Remove Download Remove Marketing Remove Therapies
article thumbnail

Accelerate your cell therapy to clinic with a flexible CGMP-ready process

Fierce BioTech

Accelerate your cell therapy to clinic with a flexible CGMP-ready process The cell therapy market holds great promise, yet faces challenges like material variability and the need for standardization. Download this whitepaper to discover how to de-risk these challenges and meet the evolving needs of the cell therapy market.

article thumbnail

Scaling Phage Therapy

Codon

Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Read it on our website here. Illustration by David S. Fast forward to 2023.

Therapies 115
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New Report: How GoodRx Improves the Economics of Healthcare

Drug Channels

Today’s guest post comes from Divya Iyer, SVP of Go-to-Market Strategy at GoodRx. She highlights how GoodRx’s integrated pharma copay cards help to improve medication access, therapy adherence, and overall health outcomes.

article thumbnail

Taking A Technology-First Approach In Your Affordability Program

Drug Channels

Today’s guest post comes from Stacey Little, Senior Vice President of Business Development and Marketing at AssistRx. Stacey discusses digital hubs and the affordability advantages they offer both patients on specialty therapies and their health care providers.

article thumbnail

How combining datasets from multiple sources can inform and improve commercial strategies

Fierce BioTech

How combining datasets from multiple sources can inform and improve commercial strategies Hundreds of rare disease treatments have entered the market over the past decade—thanks largely to a combination of government incentives, strong urging from patient advocacy groups and advances in cell and gene therapies.

article thumbnail

eBook: Unlocking Undruggable Targets

DrugBank

You’ll discover real-world examples, such as the transformation of KRAS from an undruggable target to a success story in targeted therapy. We provide insights into how you can improve efficiency, success rates, and ultimately bring more effective therapies to market.

article thumbnail

Corlieve Therapeutics SAS Closes Seed Financing to Develop Therapies for Severe Neurological Conditions

The Pharma Data

Corlieve’s lead program employs a novel AAV gene therapy approach for the treatment of refractory temporal lobe epilepsy (TLE), the most commonly diagnosed focal epilepsy in humans. Maryland , US), a leading gene therapy company. Maryland , US), a leading gene therapy company. PARIS , Nov.